Affimed N.V. (AFMD) and Cytokinetics Incorporated (NASDAQ:CYTK) Comparing side by side

Affimed N.V. (NASDAQ:AFMD) and Cytokinetics Incorporated (NASDAQ:CYTK) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed N.V. 3 0.00 N/A -0.17 0.00
Cytokinetics Incorporated 10 21.53 N/A -1.93 0.00

Demonstrates Affimed N.V. and Cytokinetics Incorporated earnings per share (EPS), gross revenue and valuation.


Table 2 has Affimed N.V. and Cytokinetics Incorporated’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Affimed N.V. 0.00% -22.7% -11.2%
Cytokinetics Incorporated 0.00% -269.2% -47.5%

Risk & Volatility

Affimed N.V.’s current beta is 2.79 and it happens to be 179.00% more volatile than S&P 500. Competitively, Cytokinetics Incorporated’s 65.00% volatility makes it more volatile than S&P 500, because of the 1.65 beta.


The Current Ratio and Quick Ratio of Affimed N.V. are 3.2 and 3.2 respectively. Its competitor Cytokinetics Incorporated’s Current Ratio is 7.1 and its Quick Ratio is 7.1. Cytokinetics Incorporated can pay off short and long-term obligations better than Affimed N.V.

Analyst Ratings

Affimed N.V. and Cytokinetics Incorporated Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Affimed N.V. 0 0 1 3.00
Cytokinetics Incorporated 0 0 3 3.00

Affimed N.V.’s upside potential is 198.51% at a $8 average price target. Meanwhile, Cytokinetics Incorporated’s average price target is $15, while its potential upside is 14.77%. The data provided earlier shows that Affimed N.V. appears more favorable than Cytokinetics Incorporated, based on analyst opinion.

Insider and Institutional Ownership

Institutional investors held 41.7% of Affimed N.V. shares and 70.9% of Cytokinetics Incorporated shares. About 8.15% of Affimed N.V.’s share are held by insiders. Comparatively, 1% are Cytokinetics Incorporated’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Affimed N.V. 2.74% 1.01% -11.76% -10.18% 71.43% -3.54%
Cytokinetics Incorporated 4.28% 8.45% 46.51% 75.4% 63.62% 92.88%

For the past year Affimed N.V. had bearish trend while Cytokinetics Incorporated had bullish trend.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.